The innovation in personalized dosing of solid drugs!

Patients, especially children and elderly people, may need drug doses that are tailored to their body weight or to their condition.

There are currently limited suitable solutions for selecting a personalized dose of solid drug and delivering it easily and accurately.

Enabling drug titration

Reducing side effects

More than 66% of preventable adverse drug events were due to parental errors in administering drugs.

Enabling precision medicine

WHY POWDOSE

The oral drug primary packaging with dosing feature for personalized medicine

Patient-centric design focused on usability. The user will only perform 2 steps to get the right and precise needed amount of drug.

Seamless Incorporation into the Drug Product. Ready-to-use and prefilled with the oral medicine

3. Low Carbon Footprint. Made of a limited number of environmentally friendly sustainable polymers.

Extended Stability: The encapsulated container design ensures high moisture and humidity protection (desiccant can be integrated as part of the device).

Partnership

The POWDOSE solution is provided to B2B pharmaceutical customers who want to combine an innovative primary packaging dosing device with their medicine.

The drug remains in dry solid form until the administration, which enhances the in-use stability and the access to the medicine.

If you have a candidate drug that would profit from the POWDOSE solution, reach out to us! We would be happy to launch an innovation co-development program with your pharma company for tailoring the dose ranges of POWDOSE to your medicine and therapy.

The POWDOSE allows personalization of doses of solid drug.

The POWDOSE adds value to the drug product and propose a differentiation against the competition.

The POWDOSE is a platform applicable to any powder or granulate-based medicine where the dose needs to be tailored to the patient’s bodyweight and condition.

Leadership

Management

Prof Dr. John van den Anker - Chief Scientific Officer

Stéphane Baronnet - Chief Technical Officer

Thierry Jomini

Founder and CEO

15 years’ experience in leading drug delivery devices and combination products development for various application such as diabetes, Parkinson disease or hormone therapies.

Successful track record of growing a B2B company with 15 employees in pharmaceutical business.

Prof Dr. John van den Anker

Chief Scientific Officer

Eckenstein-Geigy Distinguished Professor of Pediatric Pharmacology and Head Pediatric Pharmacology, University Children’s Hospital Basel, University of Basel, Switzerland

Evan and Cindy Jones Endowed Chair in Pediatric Clinical Pharmacology and Division Chief of Clinical Pharmacology, Children’s National Hospital, Washington, DC, USA

Stéphane Baronnet

Chief Technical Officer

Expert in development of medical devices containing and dosing drug products. His knowledge encompasses mechanics, injection molding, biocompatibility, formulation, electronics, embedded software, software as a medical device, apps, machine learning models, project management as well as quality standards.

Holding key management roles in the pharmaceutical industry, Stéphane led the device engineering team at AstraZeneca's swedish site and contributed to a successful start-up venture, OnDosis, as CTO.

Strong Independent US/EU Board

Thierry Jomini

CEO - Founder (based in CH - Lausanne)

15 years’ experience in leading drug delivery devices and combination products development for various application such as diabetes, Parkinson disease or hormone therapies.

Stephen M. Perry

CEO - Founder (based in RTP/USA)

He is the CEO and Founder of Kymanox where he leads a team of 300 professionals worldwide and has been formally recognized as a top CEO in the Research Triangle Park (RTP) region. He has successfully attracted growth capital from investors and has further grown the unique Kymanox platform with the acquisition of four companies. He has also helped several CEOs raise Series A venture capital.

Greg Cash

Chairman - Founder (Minneapolis)

Transformational and innovative life sciences CEO with a proven track record of growing and turning around businesses with significant value creation. Domain expertise in medical devices, mobile and digital health and pet health. Has been Chief Executive of several medical device companies, both public and privately held, as well as run units of larger entities.

Dr. Dirk Kreder

Entrepreneur, Investor and Senior Advisor (Munich)

25 years of experience in small and mid-size biotech and global pharma companies in the US and Europe with focus on Medical Device and drug development and registration. Dirk is a recognized leader in North America, Europe, and Asia to support customers in Pharma and Biotech, especially Biosimilar developers, in their medical device needs.

Paul Dunne

Entrepreneur and Business Development Manager (Dublin/Austria)

An experienced Commercial manager in the pharmaceutical industry with over 15 years working in the CDMO and R&D field facilitating interactions with Large Pharma, Biotech and Generic manufactures. Paul was co-founder of Advande Labs. A fully GMP FDA accredited analytical laboratory servicing the international pharma, Biotech, Nutraceutical and Veterinary industry.

Corporate & Institutional Support

Latest Updates

Follow POWDOSE project

We are pleased to collaborate with University College London for the testing of the POWDOSE.

AbbatiaLabs raised capital from early-stage investor Alom Ventures!

We’ll be exhibiting at CPHI in Milan on Oct 8-10. Don’t hesitate to visit us at the booth 6SU87!

Contact / Investors

Don’t hesitate to contact us

Chemin de Pramey 18
1530 Payerne
Switzerland
info@abbatialabs.com

AbbatiaLabs is a startup specialized in innovation at the edge of medical technologies and pharmaceutical development. We want to set a new standard for the personalization of solid drugs!

We are offering the opportunity to invest responsibly and have a huge impact in children healthcare. We are keen to sustainable funding for growing our company independently.